STAT

AUGUST 14, 2024

In February 2021, I received my second Covid-19 shot — the newly developed vaccine that would eventually save millions of lives worldwide — with great anticipation. It was as if an audible dog whistle began blaring right next to me.

Vaccines 145

Vaccines 145

Pharmacy Times

SEPTEMBER 14, 2023

Compared with COVID-19 vaccination alone, recent study findings show health care workers who received both a COVID-19 booster and influenza vaccinations did not have lower immune response or more frequent adverse events.

Vaccines 139

Vaccines Immunization 139

pharmaphorum

MARCH 11, 2021

European safety regulators have launched an investigation into the safety of a batch of the Oxford University/AstraZeneca COVID-19 vaccine, as countries including Denmark suspended its use as a precaution following reports of blood clots. Batch ABV5300 was delivered to 17 EU countries and comprises 1 million doses of the vaccine.

Vaccines 131

Vaccines 131

STAT

FEBRUARY 22, 2024

After a contentious dispute, Novavax has agreed to refund up to $400 million to the international organization that purchased Covid-19 shots as part of a global vaccination program, but found itself with vaccines that were no longer needed. But as demand dried up last year, the vaccine makers kept $1.4

Vaccines 139

Vaccines 139

Drug Store News

SEPTEMBER 19, 2023

In the "Making the Most of Your Vaccines" virtual event, experts will discuss the role pharmacists, nutrition, exercise and mindfulness can play in one’s vaccination experience.

Vaccines 97

Vaccines 97

Pharmacy Times

JULY 12, 2023

A panel of experts discuss those most at risk for complications from the flu, and how flu vaccines may benefit them.

Vaccines 123

Vaccines 123

pharmaphorum

MARCH 15, 2021

Ireland and the Netherlands have joined Norway, Denmark, Bulgaria and Iceland in suspending vaccinations with Oxford/AstraZeneca’s COVID-19 vaccine, shortly after the World Health Organization came out in support of the shot. . pic.twitter.com/MAodFeVXb0. — Department of Health (@roinnslainte) March 14, 2021.

Vaccines 105

Vaccines 105

pharmaphorum

NOVEMBER 2, 2020

million tender to a software company for an artificial intelligence tool that will be used to process “the expected high volume of COVID-19 vaccine adverse drug reactions (ADRs).”. The post MHRA looks to AI to hunt for COVID-19 vaccine side effects appeared first on. The UK drugs regulator has awarded a £1.5

Vaccines 145

Vaccines 145

Pharmaceutical Technology

NOVEMBER 12, 2024

The FDA agreed for Novavax to continue trials of its vaccine combo after addressing a serious adverse event that paused trials.

Vaccines 104

Vaccines FDA 104

pharmaphorum

MARCH 8, 2021

Austrian health officials have withdrawn a batch of Oxford University/AstraZeneca’s COVID-19 vaccine after two cases of severe coagulation, one of which was fatal. The BASG said in a statement that there was no indication of a “causal relationship” with the vaccination.

Vaccines 122

Vaccines 122

pharmaphorum

JANUARY 15, 2021

J&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the virus ahead of a phase 3 trial readout due later this month. Both of these vaccines require two doses, as does the most recently approved shot from Moderna, which is due to arrive in the UK in the spring.

Vaccines 119

Vaccines Immunization FDA 119

pharmaphorum

MAY 10, 2021

A review of side effects reported with coronavirus vaccines by the EMA’s safety committee has uncovered cases of inflammation of the heart in people receiving the Pfizer/BioNTech Comirnaty shot. . It is also asking for similar data from Moderna, which manufacture a COVID-19 vaccine that like Comirnaty is based on mRNA.

Vaccines 122

Vaccines Labelling Immunization 122

pharmaphorum

MARCH 31, 2021

Germany and Canada have both slapped restrictions on the AstraZeneca vaccine, recommending its use only in older patients, because of concerns over a link with blood clots. According to STIKO the side effect occurred four to 16 days after vaccination and was predominantly seen in people under 60 years of age.

Vaccines 116

Vaccines Immunization 116

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.

Immunization 107

Immunization Vaccines Hospitals 107

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition. Moderna’s Spikevax XBB.1.5-adapted

Vaccines 110

Vaccines Immunization 110

pharmaphorum

SEPTEMBER 8, 2020

An EU consumer body has urged the European Commission to keep compensation measures in place for people who might be harmed in COVID-19 vaccine trials, responding to reports that the drug industry is lobbying to reduce liability. The BEUC is adamant that relaxing consumer protections even in such exceptional circumstances is a bad idea.

Vaccines 119

Vaccines Pharmaceutical Companies Pharmaceutical Companies 119

pharmaphorum

NOVEMBER 13, 2020

Hungary is to order a consignment of Russia’s Sputnik V COVID-19 vaccine, as the country struggles to contain the infection rate. According to press reports , the decision puts Hungary on “collision course” with the EU, which has not approved the vaccine or plans to review it either. The country has had more than 1.8

Vaccines 115

Vaccines 115

pharmaphorum

MARCH 12, 2021

EU regulators are reviewing reports of low blood platelets in patients who received any of the three approved COVID-19 vaccines from Pfizer/BioNTech, AstraZeneca and Moderna. AZ vaccine safety update. The committee said appropriate medical treatment must be available in the event of an anaphylactic event with the vaccine.

Vaccines 145

Vaccines Labelling Immunization 145

pharmaphorum

DECEMBER 10, 2020

The US government’s coronavirus vaccine chief has said that Pfizer/BioNTech’s vaccine could carry a warning that it should be avoided by people who are prone to serious allergic reactions. Both recovered after appropriate treatment. Both are recovering well.”.

Vaccines 103

Vaccines Documentation FDA 103

Pharmacy Times

APRIL 8, 2024

Investigators reported a low incidence of adverse events after simultaneous vaccination against seasonal influenza and respiratory syncytial virus.

Vaccines 107

Vaccines 107

European Pharmaceutical Review

OCTOBER 21, 2022

GSK announced Shingrix (Zoster Vaccine Recombinant, Adjuvanted), the first approved shingles vaccine to combine a non-live antigen with a GSK-made adjuvant, can prevent shingles (herpes zoster) for at least decade. An interim analysis conducted over more than four years of long-term follow-up (LTFU) showed vaccine efficacy was 81.6

Vaccines 105

Vaccines Immunization 105

pharmaphorum

AUGUST 27, 2020

Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19. There were also no serious adverse events reported. The US has also bought 100 million doses of the mRNA vaccine for more than $1.5

Vaccines 111

Vaccines Immunization 111

pharmaphorum

MARCH 18, 2021

An EMA advisory committee’s review of AstraZeneca’s COVID-19 has concluded that there is no increase in the overall risk of blood clots with this vaccine. And because the vaccine is effective in preventing COVID-19 disease – which in itself is a cause of blood clots – it “likely reduces the risk of thrombotic events overall.”.

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

DECEMBER 14, 2022

and Merck have announced that a Phase IIb trial ( NCT03897881 ) of a personalised mRNA cancer vaccine (mRNA-4157/V940), in combination with KEYTRUDA ® , Merck’s anti-PD-1 therapy, demonstrated the first randomised evidence that a personalised neoantigen approach may be beneficial in treating melanoma. Moderna, Inc.

Vaccines 116

Vaccines Immunization 116

Pharmacy Times

FEBRUARY 7, 2024

The 23-valent pneumococcal polysaccharide vaccine was most likely associated with a higher risk of immunological events for those who were immunocompromised, but the events were low.

Vaccines 139

Vaccines 139

European Pharmaceutical Review

NOVEMBER 3, 2022

GSK has announced the European Medicines Agency (EMA) has validated a marketing authorisation application (MAA) under accelerated assessment for its respiratory syncytial virus (RSV) vaccine for adults above 60. If approved, the vaccine could be the first vaccine to prevent RSV lower respiratory tract disease (LRTD) in older adults.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

AUGUST 2, 2023

A new COVID-19 vaccine has been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). Bimervax is now the ninth vaccine to be authorised by the UK’s independent medicines regulator to treat the virus. The vaccine demonstrated a strong immune response in the trial.

Vaccines 98

Vaccines Immunization 98

Pharmaceutical Technology

JUNE 24, 2022

Novavax has obtained emergency use authorization (EUA) for its Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), from the Taiwan Food and Drug Administration for use in people of the age 18 years and above. The protein-based vaccine is engineered from the genetic sequence of the SARS-CoV-2 virus’ initial strain.

Vaccines 105

Vaccines FDA 105

European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Adverse events observed with mRNA-4157 in KEYNOTE-942 remain consistent with those previously reported.

Vaccines 115

Vaccines Research Laboratories Immunization 115

pharmaphorum

FEBRUARY 8, 2021

China’s national regulator has approved Sinovac Biotech’s COVID-19 vaccine for use by the general public. This is the second vaccine approved by China’s National Medical Products Administration (NMPA). Both of the vaccines, along with another experimental vaccine from Sinopharm, have been used in China’s vaccination programme.

Vaccines 90

Vaccines Immunization 90

Pharmaceutical Technology

AUGUST 17, 2022

On August 8, Pfizer and Valneva announced the initiation of a Phase III study with their Lyme disease vaccine , bringing the prospect of an injection to prevent the condition disease one step closer to reality. This means that the vaccine works against multiple serotypes of the disease, she explains. A one-size-fits-all approach.

Vaccines 119

Vaccines 119

STAT

JUNE 17, 2024

Seth Berkley, the former head of Gavi, the Vaccine Alliance, gave voice last week to a point of view STAT has been hearing for a while about the U.S. “It’s been shocking to watch the ineptitude,” Berkley, an American currently living in Switzerland, said at an event on the future of vaccines held in London.

Vaccines 145

Vaccines 145

pharmaphorum

MARCH 8, 2022

There is no evidence that vaccination with either the Pfizer/BioNTech or Moderna’s mRNA-based COVID-19 vaccines led to the death of patients, says a study by researchers at the Centres for Disease Control and Prevention (CDC).

Vaccines 83

Vaccines 83

European Pharmaceutical Review

AUGUST 30, 2022

It has highlighted the value of cutting-edge technologies, such as messenger RNA (mRNA) vaccines, and reinforced the industry’s understanding of the power of collaboration, including with contract partners such as contract development and manufacturing organisations (CDMOs). The rise of the nasal vaccine route.

Vaccines 119

Vaccines Immunization 119

pharmaphorum

OCTOBER 26, 2020

US trials of AstraZeneca’s experimental COVID-19 vaccine AZD1222 have been cleared to restart by the FDA, several weeks after testing was suspended following a serious adverse reaction in one patient who received the shot. There are many possible factors that could have caused the event.”.

Vaccines 95

Vaccines Adverse Reactions FDA 95

European Pharmaceutical Review

JUNE 24, 2022

BioNTech has initiated construction of its first vaccine production facility in Africa. Together this network of factories will supply therapies and vaccines solely for people residing in member states of the African Union. The first set of manufacturing BioNTainers are expected to be delivered to the Kigali site by the end of 2022.

Vaccines 96

Vaccines 96

STAT

OCTOBER 11, 2023

A company that Pfizer blamed for problems with a clinical trial testing a Lyme vaccine claims that regulators gave its procedures a clean bill of health during a recent inspection. Care Access served as a contract research organization and had enrolled about 3,000 patients in the late-stage trial.

Vaccines 115

Vaccines 115